Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660265 | 0.74 | KDM4E (0.41) | MEN1KMT2ALMNAPDPK1 | |
| SCHEMBL29561649 | 0.74 | — | — | |
| SCHEMBL18905972 | 0.72 | THRB (0.31) | — | |
| SCHEMBL19229111 | 0.70 | — | — | |
| SCHEMBL31303148 | 0.70 | — | — | |
| SCHEMBL20265769 | 0.69 | MAPT (0.34) | MEN1KMT2ALMNA | |
| SCHEMBL3747880 | 0.69 | PSMB8 (0.35) | LMNAPSMB8 | |
| SCHEMBL21718809 | 0.69 | CA2 (0.39) | — | |
| SCHEMBL15686692 | 0.69 | GABRA1 (0.39) | LMNA | |
| SCHEMBL17468807 | 0.69 | MAPT (0.39) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270215-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-08-28 | — | — | US | disclosed |
| EP-4514802-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023208986-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-11-02 | — | — | WO | disclosed |
| US-20170155053-A1 | Molecular and Polymeric Semiconductors and Related Devices | USINVEST LLC | 2017-06-01 | — | — | US | disclosed |
| US-20170155053-A1 | Molecular and Polymeric Semiconductors and Related Devices | USINVEST LLC | 2017-06-01 | — | — | US | disclosed |
| US-20170155053-A1 | Molecular and Polymeric Semiconductors and Related Devices | USINVEST LLC | 2017-06-01 | — | — | US | disclosed |
| WO-2016025632-A1 | MOLECULAR AND POLYMERIC SEMICONDUCTORS AND RELATED DEVICES | POLYERA CORPORATION (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016025632-A1 | MOLECULAR AND POLYMERIC SEMICONDUCTORS AND RELATED DEVICES | POLYERA CORPORATION (US) | 2016-02-18 | — | — | WO | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2534156-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2011100502-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | BACE1 828/4885MEN1 296/4885KMT2A 669/4885 |
| US-20250270215-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, TGFBR2 | BACE1 1036/4885MEN1 3451/4885KMT2A 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.